What happened with FHTX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Foghorn Therapeutics is a clinical-stage biotechnology company developing potential medicines for cancer. Its Gene Traffic Control platform studies the machinery that controls gene activity—the chromatin regulatory system—to identify targets for new drugs. It has no approved products and has never earned revenue from drug sales.
Its revenue comes entirely from its relationship with Eli Lilly. Lilly has provided upfront funding for joint drug research and development, and Foghorn earns collaboration revenue as that work progresses. Its most advanced candidate, FHD-909, blocks a protein called SMARCA2 and is in a Phase 1 trial led by Lilly, primarily in patients with non-small cell lung cancer. Its other candidates remain preclinical.
Foghorn can influence, but does not control, Lilly’s development of partnered candidates. Bringing a medicine to market depends on demonstrating safety and effectiveness and obtaining regulatory approval. The company also needs additional funding to advance its research and development.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Foghorn’s prospects hinge on Lilly-backed clinical progress validating chromatin-targeted medicines, with CellCentric and C4 Therapeutics adding competition beyond this list.
Lilly pays Foghorn for joint drug-development work and leads the Phase 1 trial of FHD-909, Foghorn’s most advanced candidate, tying Foghorn’s revenue and clinical progress to its partner. Watch Lilly’s trial updates in non-small cell lung cancer and the collaboration revenue Foghorn recognizes as work advances.
IDEAYA Biosciences and Foghorn develop cancer medicines aimed at genetic vulnerabilities, and Foghorn names IDEAYA’s targeted therapies as competitors for the same indications. IDEAYA’s clinical progress in its MTAP-pathway and other targeted programs is worth watching for changes in the competition Foghorn faces.
Prelude Therapeutics and Foghorn both develop precision cancer medicines using small molecules and drugs that remove selected proteins, so clinical validation and drugmakers’ willingness to license these approaches matter to both. Watch whether Incyte exercises its option to buy Prelude’s JAK2 V617F program, a concrete test of partner demand for Prelude’s precision-oncology work.
Nurix Therapeutics and Foghorn both develop medicines that make cells remove selected proteins and earn revenue from pharmaceutical partners, exposing both to demand for protein-degradation research. Watch Nurix’s collaboration revenue from Gilead, Sanofi and Pfizer as a readout of partner spending on this approach, rather than sales of approved drugs.
Arvinas and Foghorn both develop medicines that remove disease-related proteins, making evidence on these drugs’ efficacy, safety and pharmaceutical partnerships relevant to both. Watch the commercialization partner Arvinas and Pfizer select for vepdegestrant as a sign of interest in bringing a protein-degrader medicine to market.
Fed Interest Rate Decision
The Fed’s policy rate shapes what Foghorn earns on its cash and marketable securities and what it may pay to borrow as it funds drug research and development.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can lift interest income on Foghorn’s cash and marketable securities, while making any new borrowing costlier as it funds research and development.
If it comes in below expectations
Lower rates can reduce interest income on Foghorn’s cash and marketable securities, while making any new borrowing cheaper as it funds research and development.
Eli Lilly & Co. earningsLLY
Eli Lilly’s report and disclosures will show how the FHD-909 trial it leads and its drug-development work with Foghorn Therapeutics are progressing.
Watch Lilly’s disclosures on the FHD-909 trial alongside the collaboration revenue Foghorn recognizes from Lilly. Trial progress with rising revenue would show Lilly is advancing the program and Foghorn is recognizing more collaboration work; limited progress or lower revenue would leave the pace and financial contribution of this lead partnership uncertain.
Foghorn Therapeutics Inc. earningsThis company
Foghorn Therapeutics has no marketed product and earns revenue from research work with Lilly, so this report will show how collaboration revenue and operating cash use are changing.
Read Lilly collaboration revenue alongside cash used in operating activities. Rising revenue with lower cash use would mean collaboration work is bringing in more while the company spends less cash to run the business; falling revenue or higher cash use would show that research still requires substantial outside funding.
IDEAYA Biosciences, Inc. earningsIDYA
IDEAYA Biosciences’ report will show clinical progress in its MTAP-pathway and other targeted programs, a read on whether cancer-drug approaches competing with Foghorn Therapeutics are advancing.
Watch IDEAYA’s disclosed clinical progress in MTAP-pathway and other targeted programs. Advancing programs would show that competing treatments aimed at genetic vulnerabilities are moving forward, making the competitive pressure on Foghorn Therapeutics more tangible; limited progress would mean less evidence of that competition advancing.
